These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

466 related articles for article (PubMed ID: 32992409)

  • 1. SARS-COV-2 (COVID-19): Cellular and biochemical properties and pharmacological insights into new therapeutic developments.
    Parlakpinar H; Gunata M
    Cell Biochem Funct; 2021 Jan; 39(1):10-28. PubMed ID: 32992409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status.
    Guo YR; Cao QD; Hong ZS; Tan YY; Chen SD; Jin HJ; Tan KS; Wang DY; Yan Y
    Mil Med Res; 2020 Mar; 7(1):11. PubMed ID: 32169119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contributions of human ACE2 and TMPRSS2 in determining host-pathogen interaction of COVID-19.
    Senapati S; Banerjee P; Bhagavatula S; Kushwaha PP; Kumar S
    J Genet; 2021; 100(1):. PubMed ID: 33707363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19).
    Bourgonje AR; Abdulle AE; Timens W; Hillebrands JL; Navis GJ; Gordijn SJ; Bolling MC; Dijkstra G; Voors AA; Osterhaus AD; van der Voort PH; Mulder DJ; van Goor H
    J Pathol; 2020 Jul; 251(3):228-248. PubMed ID: 32418199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Designing therapeutic strategies to combat severe acute respiratory syndrome coronavirus-2 disease: COVID-19.
    Rohilla S
    Drug Dev Res; 2021 Feb; 82(1):12-26. PubMed ID: 33216381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Two-Way Switch Role of ACE2 in the Treatment of Novel Coronavirus Pneumonia and Underlying Comorbidities.
    Pang XC; Zhang HX; Zhang Z; Rinkiko S; Cui YM; Zhu YZ
    Molecules; 2020 Dec; 26(1):. PubMed ID: 33396184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biological, clinical and epidemiological features of COVID-19, SARS and MERS and AutoDock simulation of ACE2.
    Zhang XY; Huang HJ; Zhuang DL; Nasser MI; Yang MH; Zhu P; Zhao MY
    Infect Dis Poverty; 2020 Jul; 9(1):99. PubMed ID: 32690096
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SARS-CoV-2 receptor ACE2-dependent implications on the cardiovascular system: From basic science to clinical implications.
    Groß S; Jahn C; Cushman S; Bär C; Thum T
    J Mol Cell Cardiol; 2020 Jul; 144():47-53. PubMed ID: 32360703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SARS-CoV-2 pandemic and research gaps: Understanding SARS-CoV-2 interaction with the ACE2 receptor and implications for therapy.
    Datta PK; Liu F; Fischer T; Rappaport J; Qin X
    Theranostics; 2020; 10(16):7448-7464. PubMed ID: 32642005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
    Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
    Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Scientific Hypothesis for Treatment of COVID-19's Lung Lesions by Adjusting ACE/ACE2 Imbalance.
    Ferrara F; Vitiello A
    Cardiovasc Toxicol; 2021 Jun; 21(6):498-503. PubMed ID: 33835386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Can Host Cell Proteins Like ACE2, ADAM17, TMPRSS2, Androgen Receptor be the Efficient Targets in SARS-CoV-2 Infection?
    Gupta VK; Murthy MK; Patil S
    Curr Drug Targets; 2021; 22(10):1149-1157. PubMed ID: 33243116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of Angiotensin-Converting Enzyme 2: A Potential Target to Prevent COVID-19?
    Hu Y; Liu L; Lu X
    Front Endocrinol (Lausanne); 2021; 12():725967. PubMed ID: 34745001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The renin-angiotensin system and specifically angiotensin-converting enzyme 2 as a potential therapeutic target in SARS-CoV-2 infections.
    Ferrara F; Vitiello A
    Naunyn Schmiedebergs Arch Pharmacol; 2021 Jul; 394(7):1589-1593. PubMed ID: 34151392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interactions between ACE2 and SARS-CoV-2 S Protein: Peptide Inhibitors for Potential Drug Developments Against COVID-19.
    Dërmaku-Sopjani M; Sopjani M
    Curr Protein Pept Sci; 2021; 22(10):729-744. PubMed ID: 34530706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Different compounds against Angiotensin-Converting Enzyme 2 (ACE2) receptor potentially containing the infectivity of SARS-CoV-2: an in silico study.
    Shahbazi B; Mafakher L; Teimoori-Toolabi L
    J Mol Model; 2022 Mar; 28(4):82. PubMed ID: 35249180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Review of SARS-CoV-2 and the Ongoing Clinical Trials.
    Tu YF; Chien CS; Yarmishyn AA; Lin YY; Luo YH; Lin YT; Lai WY; Yang DM; Chou SJ; Yang YP; Wang ML; Chiou SH
    Int J Mol Sci; 2020 Apr; 21(7):. PubMed ID: 32290293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of ACE2 receptor and the landscape of treatment options from convalescent plasma therapy to the drug repurposing in COVID-19.
    Kumar P; Sah AK; Tripathi G; Kashyap A; Tripathi A; Rao R; Mishra PC; Mallick K; Husain A; Kashyap MK
    Mol Cell Biochem; 2021 Feb; 476(2):553-574. PubMed ID: 33029696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Repurposed ACE2 Inhibitors: SARS-CoV-2 Entry Blockers of Covid-19.
    Ahmad I; Pawara R; Surana S; Patel H
    Top Curr Chem (Cham); 2021 Oct; 379(6):40. PubMed ID: 34623536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic Management with Repurposing Approaches: A Mystery During COVID-19 Outbreak.
    Chaudhury S; Kaur P; Gupta D; Anand P; Chaudhary M; Tiwari S; Mittal A; Gupta J; Kaur S; Singh VD; Dhawan D; Singh P; Sahu SK
    Curr Mol Med; 2024; 24(6):712-733. PubMed ID: 37312440
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.